MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Incyte Corp

Chiusa

SettoreSettore sanitario

87.56 0.42

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

87.37

Massimo

88.21

Metriche Chiave

By Trading Economics

Entrata

247M

405M

Vendite

163M

1.2B

P/E

Media del settore

20.031

36.442

Margine di Profitto

33.319

Dipendenti

2,617

EBITDA

324M

582M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

-0.51% downside

Dividendi

By Dow Jones

Utili prossimi

28 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3B

17B

Apertura precedente

87.14

Chiusura precedente

87.56

Notizie sul Sentiment di mercato

By Acuity

74%

26%

337 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 ott 2025, 18:13 UTC

I principali Market Mover

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 ott 2025, 17:05 UTC

I principali Market Mover

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 ott 2025, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

17 ott 2025, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 ott 2025, 22:15 UTC

Discorsi di Mercato

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 ott 2025, 21:15 UTC

Discorsi di Mercato

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 ott 2025, 21:07 UTC

Discorsi di Mercato

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 ott 2025, 21:07 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 ott 2025, 20:34 UTC

Discorsi di Mercato

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 ott 2025, 20:27 UTC

Discorsi di Mercato

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 ott 2025, 19:46 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 ott 2025, 19:45 UTC

Discorsi di Mercato

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 ott 2025, 18:45 UTC

Discorsi di Mercato

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 ott 2025, 17:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 ott 2025, 17:51 UTC

Discorsi di Mercato

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 ott 2025, 17:44 UTC

Discorsi di Mercato

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 ott 2025, 17:35 UTC

Discorsi di Mercato

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 ott 2025, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

17 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 ott 2025, 16:14 UTC

Discorsi di Mercato

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 ott 2025, 16:04 UTC

Discorsi di Mercato

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 ott 2025, 15:58 UTC

Discorsi di Mercato

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 ott 2025, 15:56 UTC

Utili

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 ott 2025, 15:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 ott 2025, 15:43 UTC

Discorsi di Mercato

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

-0.51% in calo

Previsioni per 12 mesi

Media 87.12 USD  -0.51%

Alto 115 USD

Basso 60 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

19 ratings

8

Acquista

10

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

59.52 / 62.66Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

337 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat